BioDelivery Sciences Secures Significant Expanded Preferred Coverage for BELBUCA®
15 août 2018 09h26 HE
|
BioDelivery Sciences International, Inc.
RALEIGH, N.C., Aug. 15, 2018 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ:BDSI), a leading commercial specialty pharmaceutical company dedicated to patients living with...
BioDelivery Sciences Reports Strong Second Quarter 2018 Financial Results
09 août 2018 16h05 HE
|
BioDelivery Sciences International, Inc.
BELBUCA® Continues Its Accelerated Record Prescription Growth of 80% YOY and 31% Versus the Prior Quarter Company Provides Overview of New Plan to Capitalize on Long Term Net Revenue Potential of...
BioDelivery Sciences to Present at the Jefferies 2018 Global Healthcare Conference
23 mai 2018 08h00 HE
|
BioDelivery Sciences International, Inc.
RALEIGH, N.C., May 23, 2018 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc., (NASDAQ:BDSI), a specialty pharmaceutical company with a focus in pain management and addiction medicine,...
BioDelivery Sciences Announces Agreement with Broadfin Capital on Comprehensive Plan to Strengthen Business
17 mai 2018 08h01 HE
|
BioDelivery Sciences International, Inc.
$50 Million Equity Financing Led By Broadfin Announced Separately Today Three New Independent Directors Selected by Broadfin Added To Board; Four Current Independent Directors Retiring Amends...
BioDelivery Sciences Announces Pricing of $50 Million Equity Financing
17 mai 2018 08h01 HE
|
BioDelivery Sciences International, Inc.
RALEIGH, N.C., May 17, 2018 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ:BDSI) today announced that it has entered into definitive agreements with existing institutional and...